{
    "nctId": "NCT02543710",
    "officialTitle": "Biomarker Guided Treatment in Gynaecological Cancer",
    "inclusionCriteria": "part 1:\n\nAll patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.\n* Must be FEMALE\n* Must have minimum age of 18 Years\n* Must have maximum age of 95 Years",
    "exclusionCriteria": "part 1:\n\n1. Patients who do not have endometrial cancer\n2. Patients who will or cannot give informed consent (including language barriers)\n3. Patients \\<18 years of age\n4. Patients who will not get surgical treatment for their endometrial cancer\n\nInclusion criteria part 2:\n\n1. Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with advanced disease.\n2. Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.\n\nExclusion criteria part 2:\n\n1. Patients not suffering from endometrial or epithelial ovarian cancer\n2. Patients \\<18 years of age\n3. Patients who do not agree to the proposed treatment or will receive (part of) the treatment in a non-participating centre\n4. Patients who cannot or do not want to give informed consent (including language barriers)"
}